Zenith Healthcare Limited has announced its unaudited financial results for the third quarter of FY26, demonstrating a significant turnaround in its financial performance. The pharmaceutical company's Board of Directors approved the quarterly results at a meeting held on February 12, 2026, showing marked improvement across key financial metrics.

Financial Performance Highlights

The company reported strong financial recovery in Q3FY26, with several key metrics showing substantial improvement over the previous year.

Nine-Month Performance Analysis

For the nine-month period ended December 31, 2025, Zenith Healthcare maintained its positive trajectory with consistent performance improvements.

Operational Efficiency Improvements

The company's operational metrics reflect improved cost management and efficiency. Cost of materials consumed decreased significantly to ₹83.13 lakh in Q3FY26 from ₹114.36 lakh in Q3FY25, representing a substantial reduction of 27.33%. Employee benefits expense increased to ₹52.28 lakh from ₹49.96 lakh, while other expenses rose to ₹86.37 lakh from ₹82.06 lakh in the corresponding previous quarter.

Corporate Governance and Compliance

The financial results were reviewed and approved by the Board of Directors, with statutory auditors Doshi Doshi & Co conducting a limited review of the quarterly results. The results comply with Indian Accounting Standards and SEBI Listing Obligations and Disclosure Requirements Regulations 2015. The company maintains a single reportable segment in pharmaceuticals trading as per Ind AS 108 requirements.

Capital Structure Details

Zenith Healthcare's paid-up equity share capital remains stable at ₹537.39 lakh with a face value of ₹1 per share. The company's earnings per share showed significant improvement, moving from negative ₹0.05 in Q3FY25 to positive ₹0.042 in Q3FY26, reflecting the strong operational turnaround and improved profitability metrics.

Zenith Healthcare Limited , a pharmaceutical trading company, has released its unaudited financial results for the second quarter and first half of the fiscal year 2026, ending September 30, 2025. The results paint a mixed picture of the company's performance, with a quarter-on-quarter revenue decline but a notable improvement in half-yearly profits.

Quarterly Performance

For the quarter ended September 30, 2025, Zenith Healthcare reported:

The company experienced a 9.6% decrease in revenue from operations compared to the previous quarter. Net profit also saw a decline of 9.5% quarter-on-quarter.

Half-Yearly Results

Despite the quarterly dip, the half-yearly results show improvement:

The company's revenue for the first half of FY2026 grew by 14.0% compared to the same period last year. More impressively, net profit surged by 70.9% year-over-year, indicating improved profitability.

Board Approval and Compliance

The Board of Directors approved these results at a meeting held on November 11, 2025. The financial results were reviewed by the Board of Directors and the Audit Committee before approval. The company has prepared its financial statements in accordance with the Companies (Indian Accounting Standards) Rules, 2015, and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

Segment Information

Zenith Healthcare operates in a single reportable segment - Pharmaceuticals Trading, as per the requirements of Ind AS 108.

Balance Sheet Highlights

As of September 30, 2025, Zenith Healthcare reported:

The company maintains a strong equity position, with total equity of ₹752.92 lakh against total assets of ₹1,072.03 lakh.

While Zenith Healthcare faces challenges in its quarterly performance, the overall half-yearly results demonstrate resilience and growth.